Dedicated Class IIa Pathway for Saline Flushing Devices
Australia’s Therapeutic Goods Administration (TGA) has enacted an amendment to the Therapeutic Goods (Medical Devices) Regulations 2002, introducing Clause 2.2 into Part 2 of Schedule 2.
The new rule establishes that non-invasive medical devices intended to maintain the patency of, or flush the lumen of, another medical device are classified as Class IIa, provided they contain only saline for that purpose. This specifically covers consumables such as pre-filled saline flush syringes and saline vascular access locking solutions.
Regulatory Scope and Separation from Medicinal Combinations
The regulation establishes precise technical parameters defining products eligible for the Clause 2.2 pathway:
- Composition Restricted to Pure Saline: The device must contain solely sodium chloride saline solution. If the product incorporates active medicinal substances—such as heparin, taurolidine, citrate, or antimicrobial agents—it does not fall under Clause 2.2. Such combination products remain governed by Clause 5.1 as Class III medical devices incorporating a medicine.
- Immediate Effect for New Applications: The Class IIa classification applies to all applications for inclusion in the Australian Register of Therapeutic Goods (ARTG) lodged on or after 07 September 2026. Sponsors of new devices must provide conformity assessment evidence supporting Class IIa compliance.
- Five-Year Transition for Existing ARTG Entries: For medical devices already included in the ARTG or applications officially submitted prior to 07 September 2026, the TGA provides a five-year transition period extending to September 2031. Current entries remain legally marketable throughout the transition.
Practical Steps for Sponsors and Manufacturers
Manufacturers of infusion accessories, vascular access products, and pre-filled flushing solutions should undertake structured reviews:
- Audit Solution Formulations: Verify that all pre-filled flush syringes and locking products intended for the Australian market contain exclusively saline without pharmacologically active additives.
- Establish ARTG Reclassification Timelines: Map currently listed flush syringe ARTG identifiers against the five-year transition deadline to plan conformity assessment evidence renewals without supply interruption.
- Align Conformity Documentation for New Filings: Ensure that upcoming ARTG applications are supported by appropriate Class IIa CE certificates under EU MDR or comparable recognized regulatory certifications.
Sources
- Primary official sourceUpdated classification rules for certain combination products (opens in a new tab)Therapeutic Goods Administration